Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a…

Barchart

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH

Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.

Investors Business Daily

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer

Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo Nordisk CEO takes aim at U.S. health system in Ozempic testimony

Novo Nordisk's CEO said the complexities of the U.S. healtchare system prevented access to $1,349 Wegovy.

Fortune

Analysts say market forces will lower cost of obesity drugs - Roll Call

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

Roll Call

Novo Dives — And Corbus Crashes — On Psychiatric Side Effects Of Weight-Loss Drug

Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.

Investors Business Daily

‘Ozempic changed my life’: do diabetes jabs boost the chances of conception?

As surprise pregnancies multiply, some scientists are investigating whether weight loss drugs can improve fertility in women with polycystic ovary syndrome

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple

Weight-loss drug kingpins Eli Lilly and Novo Nordisk could join the trillion-dollar company club before even Tesla, according to a report.

Investors Business Daily

The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

Investors Business Daily

Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review

Monday's global sell-off turned into a stock market rally attempt. Palantir, Eli Lilly and Fortinet were among the earnings winners.

Investors Business Daily

Denmark gets Novo Nordisk to lower Ozempic prices

As Congress pushes for Medicare to cover anti-obesity drugs, puzzlement remains about who should get them, for how long, and at what price.

Fortune

Novo Nordisk Dives On Rare Miss As Pricing Pressure Weighs On Ozempic, Wegovy

Novo Nordisk stock tumbled Wednesday after the drugmaker reported a rare sales miss for its two biggest moneymakers, Ozempic and Wegovy.

Investors Business Daily

Novo Nordisk cuts profit outlook after weaker sales of weight-loss drug Wegovy

Danish company, which also makes Ozempic, faces increasing competition from US rival Eli Lilly

The Guardian - UK

Novo Nordisk hits out as Dutch agency advises against insurance cover for Wegovy

Novo had last year applied to Dutch authorities for a coverage of the drug under its insurance

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Novo Nordisk Stock Pops After Weight-Loss Drug Cuts Dementia Risk In Yearlong Study

Novo Nordisk stock popped Friday after a study showed its diabetes and weight-loss drug could lower the risk of developing dementia.

StockNews.com

Will Novo Nordisk's (NVO) Q2 Earnings Reflect Its Market Potential?

With strong first-quarter results and promising growth in its diabetes and obesity treatments, all eyes are on Novo Nordisk’s (NVO) to see if the pharmaceutical giant can maintain its momentum. Will the upcoming second-quarter earnings report reflect its market potential? Learn more to find out….

The Independent UK

Weight-loss war heats up as Wegovy rival found to lead to faster and greater results

Shares in Novo Nordisk were down 1.1% after the study

Investors Business Daily

Novo, Lilly Tumble After Study Ties Blindness Disorder To Weight-Loss Drugs

Novo Nordisk stock skidded Wednesday after a new study suggests its diabetes and weight-loss drug can lead to a blindness-causing disease.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Novo, Lilly Fall After Biden Slams Duo For 'Unconscionably High' Drug Prices

Novo Nordisk stock fell Tuesday after Joe Biden and Bernie Sanders slammed the drugmaker and Eli Lilly for high prices of weight-loss drugs.

Kiplinger

The Future of Weight-Loss Drugs for Investors

Weight-loss drugs’ impact could reach far beyond their target user, potentially creating headwinds for shares of snack makers and packaged-food firms, as well as medical device makers that specialize in knee replacements, insulin pumps and sleep apnea machines.

Fortune

Novo Nordisk CEO to face off with Bernie Sanders over 1,300% Ozempic markup in U.S.

Novo's Danish CEO Lars Fruergaard Jørgensen will face the U.S. Senate in September to defend Wegovy's and Ozempic's eye-watering prices.

Investors Business Daily

ASML, Novo Nordisk, Spotify Boast This Sign Of Stock Market Leadership

Spotify stock, ASML and Novo Nordisk, are in or near buy zones and boast this key signal of stock market leadership.

Al Jazeera

In China, weight-loss drugs are becoming big business

Chinese pharmaceutical companies are racing to roll out weight-loss drugs amid the popularity of Ozempic.

Investors Business Daily

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points

Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.

Digital Camera World

Novo Helix T50 Carbon Fiber Tripod Kit review

This feature-packed travel tripod packs down unfeasibly small, yet extends reasonably tall

1 2 3 4 5

People

Lars Fruergaard Jørgensen

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.